These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

647 related articles for article (PubMed ID: 25658140)

  • 1. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV).
    Daikeler T; Kistler AD; Martin PY; Vogt B; Huynh-Do U
    Swiss Med Wkly; 2015; 145():w14103. PubMed ID: 25658140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach.
    Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X
    Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [ANCA-associated vasculitis].
    Holle JU
    Internist (Berl); 2015 Jan; 56(1):41-50; quiz 51-2. PubMed ID: 25502657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in the treatment of anti-neutrophil cytoplasm antibody-associated vasculitis.
    Jones RB
    Nephron Clin Pract; 2014; 128(3-4):243-9. PubMed ID: 25401382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologics for ANCA-associated vasculitis.
    Murgia G; Firinu D; Manconi PE; Del Giacco SR
    Inflamm Allergy Drug Targets; 2014; 13(4):275-87. PubMed ID: 24998311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
    Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L;
    Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis.
    Rich EN; Brown KK
    Curr Opin Pulm Med; 2012 Sep; 18(5):447-54. PubMed ID: 22854508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Therapies for ANCA-associated Vasculitis.
    Monti S; Brandolino F; Milanesi A; Xoxi B; Delvino P; Montecucco C
    Curr Rheumatol Rep; 2021 Apr; 23(6):38. PubMed ID: 33909172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
    Cartin-Ceba R; Fervenza FC; Specks U
    Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted immunotherapy strategies in ANCA-associated vasculitis.
    Puéchal X
    Joint Bone Spine; 2019 May; 86(3):321-326. PubMed ID: 30201478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ANCA-Associated Vasculitis: Core Curriculum 2020.
    Geetha D; Jefferson JA
    Am J Kidney Dis; 2020 Jan; 75(1):124-137. PubMed ID: 31358311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis: update.
    Santana AN; Woronik V; Halpern AS; Barbas CS
    J Bras Pneumol; 2011; 37(6):809-16. PubMed ID: 22241040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of ANCA-associated vasculitis: new therapies and a look at old entities.
    Zand L; Specks U; Sethi S; Fervenza FC
    Adv Chronic Kidney Dis; 2014 Mar; 21(2):182-93. PubMed ID: 24602467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics, the diagnostic criteria and management recommendation of otitis media with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (OMAAV) proposed by Japan Otological Society.
    Harabuchi Y; Kishibe K; Tateyama K; Morita Y; Yoshida N; Okada M; Kunimoto Y; Watanabe T; Inagaki A; Yoshida T; Imaizumi M; Nakamura T; Matsunobu T; Kobayashi S; Iino Y; Murakami S; Takahashi H; Tono T
    Auris Nasus Larynx; 2021 Feb; 48(1):2-14. PubMed ID: 32768313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.
    Guillevin L; Pagnoux C; Karras A; Khouatra C; Aumaître O; Cohen P; Maurier F; Decaux O; Ninet J; Gobert P; Quémeneur T; Blanchard-Delaunay C; Godmer P; Puéchal X; Carron PL; Hatron PY; Limal N; Hamidou M; Ducret M; Daugas E; Papo T; Bonnotte B; Mahr A; Ravaud P; Mouthon L;
    N Engl J Med; 2014 Nov; 371(19):1771-80. PubMed ID: 25372085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis: classification, diagnosis, and treatment.
    Lally L; Spiera R
    Rheum Dis Clin North Am; 2015; 41(1):1-19, vii. PubMed ID: 25399936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis: advances in pathogenesis and treatment].
    Silva F; Cisternas M
    Rev Med Chil; 2013 Jun; 141(6):765-73. PubMed ID: 24121580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate versus cyclophosphamide for remission maintenance in ANCA-associated vasculitis: A randomised trial.
    Maritati F; Alberici F; Oliva E; Urban ML; Palmisano A; Santarsia F; Andrulli S; Pavone L; Pesci A; Grasselli C; Santi R; Tumiati B; Manenti L; Buzio C; Vaglio A
    PLoS One; 2017; 12(10):e0185880. PubMed ID: 29016646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.
    Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR;
    Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in ANCA-Associated Vasculitis.
    Hassan RI; Gaffo AL
    Curr Rheumatol Rep; 2017 Feb; 19(2):6. PubMed ID: 28155022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.